Novonesis Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Novonesis has a total shareholder equity of €11.0B and total debt of €2.0B, which brings its debt-to-equity ratio to 18.1%. Its total assets and total liabilities are €15.3B and €4.2B respectively. Novonesis's EBIT is €525.0M making its interest coverage ratio 15.7. It has cash and short-term investments of €260.8M.

Anahtar bilgiler

18.1%

Borç/özkaynak oranı

€1.99b

Borç

Faiz karşılama oranı15.7x
Nakit€260.80m
Eşitlik€11.01b
Toplam yükümlülükler€4.25b
Toplam varlıklar€15.25b

Son finansal sağlık güncellemeleri

Recent updates

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

Sep 27
These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

An Intrinsic Calculation For Novozymes A/S (CPH:NZYM B) Suggests It's 22% Undervalued

Sep 05
An Intrinsic Calculation For Novozymes A/S (CPH:NZYM B) Suggests It's 22% Undervalued

Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Jul 09
Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Jun 24
Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

May 02
Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Apr 07
Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Mar 26
Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Is Now The Time To Put Novozymes (CPH:NZYM B) On Your Watchlist?

Mar 12
Is Now The Time To Put Novozymes (CPH:NZYM B) On Your Watchlist?

Novozymes' (CPH:NZYM B) Profits Appear To Have Quality Issues

Feb 04
Novozymes' (CPH:NZYM B) Profits Appear To Have Quality Issues

Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Jan 29
Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Is Novozymes (CPH:NZYM B) Using Too Much Debt?

Dec 23
Is Novozymes (CPH:NZYM B) Using Too Much Debt?

Returns On Capital At Novozymes (CPH:NZYM B) Paint A Concerning Picture

Dec 05
Returns On Capital At Novozymes (CPH:NZYM B) Paint A Concerning Picture

A Look At The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)

Oct 14
A Look At The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

Sep 13
These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

The Returns On Capital At Novozymes (CPH:NZYM B) Don't Inspire Confidence

Aug 29
The Returns On Capital At Novozymes (CPH:NZYM B) Don't Inspire Confidence

Estimating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Jul 13
Estimating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Here's Why Novozymes (CPH:NZYM B) Can Manage Its Debt Responsibly

Jun 13
Here's Why Novozymes (CPH:NZYM B) Can Manage Its Debt Responsibly

Here's What's Concerning About Novozymes' (CPH:NZYM B) Returns On Capital

May 29
Here's What's Concerning About Novozymes' (CPH:NZYM B) Returns On Capital

Estimating The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)

Apr 12
Estimating The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: NSIS B's short term assets (€1.8B) exceed its short term liabilities (€1.6B).

Uzun Vadeli Yükümlülükler: NSIS B's short term assets (€1.8B) do not cover its long term liabilities (€2.6B).


Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: NSIS B's net debt to equity ratio (15.7%) is considered satisfactory.

Borcun Azaltılması: NSIS B's debt to equity ratio has reduced from 36.2% to 18.1% over the past 5 years.

Borç Kapsamı: NSIS B's debt is well covered by operating cash flow (44.8%).

Faiz Kapsamı: NSIS B's interest payments on its debt are well covered by EBIT (15.7x coverage).


Bilanço


Sağlıklı şirketleri keşfedin